Prognostic significance of leukopenia at the time of diagnosis in acute myeloid leukemia

Clinical Lymphoma, Myeloma and Leukemia

Volumn 11, Issue 5, 2011, Pages 427-432

  Arellano, Martha ^a   Bernal Mizrachi, Leon ^a   Pan, Lin ^a   Tighiouart, Mourad ^a   Souza, Liliana ^a   Guo, Xiangxue ^a   McLemore, Morgan ^a   Lima, Lisa ^a   Sunay, Susan ^a   Heffner, Leonard T ^a   Chen, Zhengjia ^a   Chen, Georgia Zhou ^a   Langston, Amelia ^a   Winton, Elliott ^a   Khoury, H Jean ^a  

^a EMORY UNIVERSITY   (United States)

Author keywords

Acute myelogenous leukemia (AML); Adults; Leukopenia; Outcomes; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; CD135 ANTIGEN; CD31 ANTIGEN; CD34 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; MITOXANTRONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; STEM CELL FACTOR RECEPTOR; VERY LATE ACTIVATION ANTIGEN; VERY LATE ACTIVATION ANTIGEN 2; VERY LATE ACTIVATION ANTIGEN 4; VERY LATE ACTIVATION ANTIGEN 5; CELL ADHESION MOLECULE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER REGRESSION; CANCER SURVIVAL; CONTROLLED STUDY; DRUG MEGADOSE; DRUG RESPONSE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LEUKOCYTE COUNT; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; RECEIVER OPERATING CHARACTERISTIC; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; ADOLESCENT; AGE; COHORT ANALYSIS; CONSOLIDATION CHEMOTHERAPY; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; PROGNOSIS; REMISSION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CELL ADHESION MOLECULES; COHORT STUDIES; CONSOLIDATION CHEMOTHERAPY; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOID, ACUTE; LEUKOPENIA; MALE; MIDDLE AGED; PROGNOSIS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 81255161085     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2011.03.035     Document Type: Article

References (19)

1. Porcu P, Cripe LD, Ng EW, et al. Hyperleukocytic leukemias and leukostasis: a review of pathophysiology, clinical presentation and management. Leuk Lymphoma 2000; 39:1-18. (Pubitemid 30662024)
2. Appelbaum FR, Rowe JM, Radich J, et al. Acute myeloid leukemia. Hematology Am Soc Hematol Educ Program 2001:62-86.
3. Larson RA. Is secondary leukemia an independent poor prognostic factor in acute myeloid leukemia? Best Pract Res Clin Haematol 2007; 20:29-37.
4. Valk PJ, Verhaak RG, Beijen MA, et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med 2004; 350:1617-28. (Pubitemid 38528701)
5. Dutcher JP, Schiffer CA, Wiernik PH. Hyperleukocytosis in adult acute nonlym-phocytic leukemia: impact on remission rate and duration, and survival. J Clin Oncol 1987; 5:1364-72.
6. Thiebaut A, Thomas X, Belhabri A, et al. Impact of pre-induction therapy leu-kapheresis on treatment outcome in adult acute myelogenous leukemia presenting with hyperleukocytosis. Ann Hematol 2000; 79:501-6.
7. Greenwood MJ, Seftel MD, Richardson C, et al. Leukocyte count as a predictor of death during remission induction in acute myeloid leukemia. Leuk Lymphoma 2006; 47:1245-52. (Pubitemid 44269630)
8. Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 1985; 103:620-5.
9. Harris NL, Jaffe ES, Diebold J, et al. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. Ann Oncol 1999; 10:1419-32. (Pubitemid 30017051)
10. Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000; 96:4075-83.
11. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003; 21:4642-9. (Pubitemid 46594039)
12. Asou N, Adachi K, Tamura J, et al. Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Japan Adult Leukemia Study Group. J Clin Oncol 1998; 16:78-85. (Pubitemid 28041582)
13. Hoelzer D, Gokbuget N, Ottmann O, et al. Acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2002:162-92.
14. Rombouts EJ, Pavic B, Lowenberg B, et al. Relation between CXCR-4 expression, Flt3 mutations, and unfavorable prognosis of adult acute myeloid leukemia. Blood 2004; 104:550-7. (Pubitemid 38900040)
15. Spoo AC, Lubbert M, Wierda WG, et al. CXCR4 is a prognostic marker in acute myelogenous leukemia. Blood 2007; 109:786-91. (Pubitemid 46105982)
16. Vila L, Thomas X, Campos L, et al. Expression of VLA molecules on acute leukemia cells: relationship with disease characteristics. Exp Hematol 1995; 23:514-8.
17. Thomas X, Anglaret B, Bailly M, et al. Differential adhesiveness between blood and marrow leukemic cells having similar pattern of VLA adhesion molecule expression. Leuk Res 1998; 22:953-60. (Pubitemid 28438306)
18. Konoplev S, Rassidakis GZ, Estey E, et al. Overexpression of CXCR4 predicts adverse overall and event-free survival in patients with unmutated FLT3 acute myeloid leukemia with normal karyotype. Cancer 2007; 109:1152-6. (Pubitemid 46435395)
19. Costantini A, Mancini S, Giuliodoro S, et al. Effects of cryopreservation on lymphocyte immunophenotype and function. J Immunol Methods 2003; 278:145-55. (Pubitemid 37281198)